Loading...
Printed on 6/29/2026
For informational purposes only. This is not medical advice.
The Mini-Mental State Examination (MMSE), developed by Folstein et al. in 1975, is one of the most widely used cognitive screening tools. It tests orientation (10 points), registration (3 points), attention/calculation (5 points), recall (3 points), language (8 points), and visuospatial construction (1 point) for a total of 30 points. A score ≥24 is generally considered normal, 19–23 suggests mild cognitive impairment, 10–18 moderate impairment, and <10 severe impairment. While the MoCA has replaced it in some settings, the MMSE remains the most cited cognitive test in medicine. Note: this tool interprets the total score — the MMSE itself is a copyrighted instrument.
Formula: Total score 0–30. Normal ≥24. Mild 19–23. Moderate 10–18. Severe <10.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
A trained clinician or trained staff member administers the full Mini-Mental State Examination face-to-face. The exam covers six cognitive domains: orientation to time and place (10 points), registration of three words (3 points), attention and calculation using serial 7s or spelling WORLD backwards (5 points), recall of the three registered words (3 points), language tasks including naming, repetition, three-step commands, reading, writing, and copying (8 points), and visuospatial construction by copying an intersecting pentagon (1 point). The entire administration takes 5 to 10 minutes in most patients. Standardized administration is important because examiner variability can affect scores, particularly for borderline cases.
After completing the examination, the clinician totals the raw points earned across all domains to produce a final score between 0 and 30. Each correctly completed item contributes its designated points, and partial credit is not typically awarded except where the scoring instructions specify alternatives (for example, accepting WORLD spelled backwards instead of serial 7s). The serial 7s and WORLD backwards subtask allows administering the task the patient can better perform, with credit given for whichever task is attempted. Accurate summation is essential because small score differences near cutoffs (for example, 23 versus 24) carry meaningful clinical implications.
The raw total is interpreted using established cutoff bands: a score of 24 to 30 is generally considered within normal limits for the average adult, 19 to 23 suggests mild cognitive impairment or early dementia, 10 to 18 suggests moderate impairment, and a score below 10 indicates severe impairment. Critically, these cutoffs should be adjusted for education level — patients with fewer than 8 years of formal education have lower expected scores and may be falsely classified as impaired, while highly educated individuals may harbor meaningful decline while still scoring above 24. Serial testing over time adds significant interpretive value, as a decline of 3 to 4 points per year is characteristic of Alzheimer disease progression. The MMSE score alone does not establish a diagnosis; it provides a quantitative snapshot to guide further evaluation.
Primary care physicians, geriatricians, geriatric nurse practitioners
The MMSE is the most commonly used first-line cognitive screening tool when a patient, family member, or caregiver reports concerns about memory loss or cognitive decline. In primary care and geriatric clinics, it provides a quantitative baseline that can be documented in the medical record and tracked over subsequent visits. A score below 24 triggers further workup including laboratory evaluation (thyroid, B12, metabolic panel), neuroimaging, and often referral to neurology or geriatric psychiatry. Because the MMSE has been used for decades, clinicians are familiar with interpreting it and large normative databases exist. It remains the most cited cognitive test in the dementia literature, making results easily communicable between providers.
Neurologists, geriatric psychiatrists, dementia care teams
Once a diagnosis of Alzheimer disease or another progressive dementia has been established, the MMSE is used to track cognitive decline over time. Annual MMSE administration allows clinicians to quantify the rate of progression, typically 2 to 4 points per year in untreated Alzheimer disease. This information helps with care planning, driving evaluations, legal capacity assessments, and medication decisions such as initiating cholinesterase inhibitors or anti-amyloid therapies. It is particularly well suited for moderate to severe dementia, where it provides better resolution than tools like the MoCA whose ceiling effect operates differently in this population. Serial MMSE scores are frequently required documentation for dementia-related legal proceedings and insurance coverage decisions.
Intensivists, hospitalists, critical care nurses
The MMSE is sometimes used alongside or as a supplement to the Confusion Assessment Method (CAM) in hospitalized patients being evaluated for delirium. A rapidly fluctuating MMSE score over hours or days is characteristic of delirium, whereas a more gradual decline over months is typical of dementia. In the ICU, cognitive assessment helps guide sedation management, identify superimposed delirium in patients with underlying dementia, and establish whether pre-admission cognitive function was intact. Clinicians should be aware that MMSE scores in the acute hospital setting are often confounded by pain, opioid medications, metabolic derangements, and sleep deprivation — all of which can lower scores transiently. Repeating the MMSE after delirium resolves is essential before drawing conclusions about baseline cognitive status.
Anesthesiologists, surgeons, perioperative nurses
Establishing a pre-operative MMSE baseline is important for patients undergoing major surgery, particularly cardiac surgery, orthopedic procedures, or any operation requiring general anesthesia in older adults. Post-operative cognitive dysfunction (POCD) is a recognized complication, and documenting pre-operative cognitive status allows clinicians to distinguish new post-operative decline from pre-existing impairment. A pre-operative MMSE below 24 is associated with higher risk of POCD, delirium, and prolonged hospital stay, and may influence intra-operative anesthetic management. Many enhanced recovery after surgery (ERAS) protocols now recommend pre-operative cognitive screening as standard care for patients over 65. The MMSE provides a brief, standardized way to fulfill this requirement.
Clinical researchers, pharmaceutical investigators, regulatory affairs specialists
The MMSE has been used as a primary or secondary endpoint in hundreds of Alzheimer disease drug trials, including the landmark trials of donepezil, rivastigmine, galantamine, and more recently lecanemab and donanemab. Regulatory agencies including the FDA and EMA are familiar with MMSE as an outcome measure, and its extensive normative database allows standardized comparisons across trial sites globally. In clinical practice, it can be used to monitor whether a patient prescribed a cholinesterase inhibitor is showing expected stabilization or continuing decline. A stable MMSE over 6 to 12 months in a patient started on an anti-dementia medication is generally considered a favorable treatment response, given that untreated Alzheimer disease typically produces measurable annual decline.
Education level is one of the most important covariates affecting MMSE performance. Patients with fewer than 8 years of formal education can score 2 to 4 points lower than average-education peers without any cognitive pathology. Conversely, highly educated patients (16+ years) can score 28 to 30 and still be experiencing meaningful cognitive decline from their personal baseline. When interpreting borderline scores (22 to 25), always document education level and consider whether the score is consistent with the patient's premorbid intellectual function. Education-adjusted normative tables are available and should be used when formal neuropsychological testing is not feasible.
The MMSE has a well-documented ceiling effect, meaning patients with mild cognitive impairment (MCI) frequently score 26 to 30 and are classified as normal. This is because the MMSE's memory, attention, and executive function tasks are not sufficiently difficult to detect early-stage decline. The Montreal Cognitive Assessment (MoCA) is significantly more sensitive for MCI, with reported sensitivity of 90% versus approximately 18% for the MMSE at the standard cutoff. If a patient complains of memory problems but scores 26 or above on the MMSE, administering the [MoCA Score](/tools/moca-score) is strongly recommended before reassuring the patient that cognition is normal.
The attention and calculation domain allows examiners to administer either serial 7 subtractions from 100 (5 points) or spelling WORLD backwards (5 points). Standard scoring gives credit for whichever task the patient attempts; however, the tasks are not equivalent in difficulty and some patients perform better on one than the other. If there is any concern about accurately assessing attention, administer both tasks and document results. Note that performance on this domain is heavily influenced by educational background and anxiety. A low score on this item in an otherwise intact assessment should not be overweighted.
While a gradual decline to below 10 may represent end-stage Alzheimer disease or another progressive dementia, an acute drop to this range in a patient who was previously cognitively intact is a medical emergency requiring urgent evaluation. Conditions causing rapid cognitive decline include encephalitis, subdural hematoma, metabolic encephalopathy, CNS vasculitis, prion disease, and rapidly progressive dementias. Do not attribute a score below 10 to slow progressive dementia without first ruling out treatable etiologies. Urgent neuroimaging (CT or MRI), lumbar puncture if indicated, and laboratory evaluation are necessary in this scenario.
Delirium is one of the most common causes of an acutely low MMSE in hospitalized patients. A patient with previously intact cognition can score as low as 10 to 15 during a severe delirious episode due to impaired attention, disorientation, and psychomotor slowing. Treating the underlying cause of delirium (infection, medication toxicity, pain, sleep deprivation) will typically restore the MMSE toward baseline over days to weeks. Never diagnose dementia based on a single MMSE performed during an acute delirious episode. Always document that the assessment was performed during delirium and plan to repeat after full recovery.
Major depression and severe anxiety can cause pseudodementia, where cognitive performance is impaired by mood disorder rather than neurodegeneration. Patients with active depression may score 2 to 4 points lower on the MMSE than their true cognitive baseline, particularly on recall and attention tasks. When depression is suspected, it is clinically appropriate to initiate antidepressant treatment and repeat the MMSE after 6 to 8 weeks once mood has improved. A meaningful score improvement after depression treatment suggests that the cognitive impairment was at least partially mood-related, while persistent low scores despite mood improvement suggest coexistent neurodegenerative disease.
The MMSE's greatest clinical value is in monitoring the rate of cognitive decline in patients already diagnosed with moderate to severe dementia, not in detecting early-stage disease. In this context, it provides a reliable, reproducible numerical anchor that can be used across clinical visits, care settings, and providers. For patients where the question is whether early cognitive impairment is present, the [MoCA Score](/tools/moca-score) is more appropriate. For patients where the question is how fast a known dementia is progressing or whether treatment is helping, the MMSE remains a valuable tool. Understanding this distinction helps clinicians avoid the most common MMSE error: using it to rule out mild cognitive impairment.
Your MMSE score provides a snapshot of global cognitive function across several domains. A score of 24 to 30 is generally considered normal, though highly educated individuals may score 30 and still harbor early cognitive decline. A score of 19 to 23 suggests mild cognitive impairment, indicating subtle difficulties with memory, orientation, or language that may warrant further neuropsychological testing. A score of 10 to 18 suggests moderate cognitive impairment, typically associated with functional difficulties in daily activities such as managing finances or medications. A score below 10 indicates severe impairment, often seen in advanced dementia where the individual requires substantial assistance with basic activities of daily living.
It is important to recognize that the MMSE score alone does not establish a diagnosis of dementia or any specific neurodegenerative condition. The score must be interpreted within the clinical context, including the patient's baseline education level, language proficiency, and any acute conditions such as delirium or depression that can transiently lower scores.
The MMSE is most commonly used as a bedside cognitive screening tool during initial evaluation of patients with suspected cognitive decline or dementia. It is appropriate in primary care, geriatric medicine, neurology, and psychiatry settings. Clinicians use it to establish a baseline cognitive score, track progression over serial assessments, and document cognitive status for care planning or medicolegal purposes.
The MMSE is also frequently used in clinical trials as an inclusion/exclusion criterion and as an outcome measure for Alzheimer disease treatments. It is well suited for patients with moderate to severe dementia, where its scoring range provides adequate resolution. For detecting mild cognitive impairment, the Montreal Cognitive Assessment (MoCA) may be a more sensitive alternative.
The MMSE has a well-documented ceiling effect, meaning many patients with mild cognitive impairment or early-stage dementia score in the normal range (24 or above). It is particularly insensitive to executive dysfunction, frontal lobe pathology, and visuospatial deficits. As a result, patients with frontotemporal dementia, Lewy body dementia, or vascular cognitive impairment may be missed.
Education level significantly affects MMSE performance. Individuals with less formal education may score lower even without cognitive impairment, while highly educated individuals may compensate and score normally despite meaningful decline. Age and cultural background also influence results, and standard cutoffs may not apply equally across all populations.
The MMSE is a copyrighted instrument (owned by Psychological Assessment Resources), which has led many institutions to adopt the freely available MoCA instead. The MMSE also takes only 5 to 10 minutes and samples a limited range of cognitive abilities, so abnormal scores should always prompt more comprehensive neuropsychological evaluation.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Interpret Montreal Cognitive Assessment (MoCA) scores. The leading cognitive screening tool for mild cognitive impairment and dementia.
OpenGeriatricsScreen for delirium using the CAM (Confusion Assessment Method). Gold standard with ~94% sensitivity and ~89% specificity. Requires acute onset + inattention, plus disorganized thinking or altered consciousness.
OpenGeriatricsAssess frailty using the Rockwood Clinical Frailty Scale (CFS 1–9): Very Fit to Terminally Ill. Used for hospice eligibility, prognostication, ICU triage, surgical risk stratification, and goals-of-care discussions.
OpenEnter the total MMSE score after administering all sections (orientation, registration, attention, recall, language, construction).